NCT02365597 2026-03-19
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT04083976 2026-03-19
RAGNAR
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05567185 2026-03-13
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
NCT03390504 2026-02-02
THOR
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03473743 2025-12-23
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting